| Catalog No. |
Size |
Price |
Figures |
Z00041-1 mg
| 1 mg | $ 630.00 | References:
- Mills R, et al. Improving gene annotation of complete viral genomes. Nucleic Acids Res. Dec 2003; 31(23): 7041-7055.
- Stavrinides J, Guttman DS. Mosaic evolution of the severe acute respiratory syndrome coronavirus. J. Virol. Jan 2004; 78(1): 76-82.
- Chen Z, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. Mar 2005; 79(5): 2678-2688.
|
|---|
| Full Name | | SARS-Associated Coronavirus Spike Mosaic S (M) |
|
| Abbreviated Name-1 | SARS Coronavirus Spike mosaic S(M) |
| Description | SARS-Associated Coronavirus Spike Mosaic S is an E. coli-derived recombinant. The protein contains the middle section of the spike protein's immunodominant regions. The coronavirus's spike (S)-glycoprotein interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. |
| Purity | >95% pure as determined by 10% PAGE (coomassie staining) |
| Storage | Store at -20°C. Keep container tightly closed. Store in a cool dry place. |
| Concentration | 1 mg/ml in 25 mM Tris-HCl, 0.4% sarcosyl, 0,25% Triton-100, 50% glycerol |
| Stability | The protein will remain stable for five years if stored at -20°C and for six months if stored at +4°C. |
| Specificity | This protein is immunoreactive with the sera of SARS-infected individuals. |
| Applications | This protein serves well as an antigen in ELISA and western blot analyses. As an antigen for detection of SARS, it shows minimal specificity problems. |